Up next

Autoplay

Dr. Brentjens on CD19-Targeted T Cells in CLL and ALL

2 Views • 07/14/23
Share
Embed
administrator
administrator
Subscribers
0

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-Targeted T Cells.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay